一、募集资金基本情况 （一）募集资金到位情况 经中国证券监督管理委员会《关于同意浙江迦南科技股份有限公司向特定对 象发行股票注册的批复》（证监许可[2021]1175 号），同意公司向特定对象发行 股票的注册申请。公司向 12 名特定对象发行人民币普通股（A 股）股票 35,573,122 股，发行价格 7.59 元/股，募集资金总额为人民币 269,999,995.98 元，扣除各项 发行费用人民币 8,137,735.84 元（不含增值税），募集资金净额为人民币 261,862,260.14 元。该募集资金截至 2021 年 12 月 3 日已全部到账。上述资金到 位情况已经中汇会计师事务所（特殊普通合伙）验证，并出具了《浙江迦南科技 股份有限公司验资报告》（中汇会验[2021]7839 号）。 国投证券股份有限公司 关于浙江迦南科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查报告 国投证券股份有限公司（以下简称"国投证券"或"保荐机构"）作为浙江 迦南科技股份有限公司（以下简称"迦南科技"、"上市公司"或"公司"）2020 年度向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务管理 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,383,110,540.27, representing a 32.09% increase compared to ¥1,047,093,891.26 in 2023[18]. - Net profit attributable to shareholders was ¥36,266,978.88 in 2024, a significant turnaround from a loss of ¥23,433,467.29 in 2023, marking a 254.77% improvement[18]. - The net cash flow from operating activities increased by 289.70% to ¥119,463,611.61 in 2024, compared to a negative cash flow of ¥62,974,373.07 in 2023[18]. - Basic earnings per share improved to ¥0.07 in 2024 from a loss of ¥0.05 in 2023, reflecting a 240.00% increase[18]. - The company's total revenue for 2024 reached ¥1,383,110,540.27, representing a 32.09% increase compared to ¥1,047,093,891.26 in 2023[71]. - The pharmaceutical equipment sector generated ¥1,165,731,743.04, accounting for 84.28% of total revenue, with a year-on-year growth of 17.44%[71]. - The oral solid dosage equipment sales amounted to ¥806,565,253.23, making up 58.32% of total revenue, reflecting a 17.63% increase from the previous year[71]. - The gross profit margin for the pharmaceutical equipment industry was 28.37%, showing a slight decrease of 0.06% year-on-year[73]. - The company's revenue from the pharmaceutical equipment industry reached ¥1,165,731,743.04, with a year-on-year increase of 17.44%[73]. - Domestic sales accounted for 93.38% of total revenue, amounting to ¥1,291,535,409.58, reflecting a 32.95% increase year-on-year[73]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.6 yuan per 10 shares (including tax) based on a total of 497,756,637 shares[5]. - The company has a cash dividend amount of 29,865,398.22 CNY, which represents 100% of the total profit distribution[162]. - The cash dividend per 10 shares is 0.6 CNY, reflecting the company's commitment to returning value to shareholders[161]. - The company has a clear and transparent profit distribution policy, ensuring the protection of minority shareholders' rights[160]. - The company has not issued any bonus shares or stock increases during the reporting period[162]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[5]. - The company has outlined potential risks and corresponding countermeasures in its management discussion and analysis section[5]. - The company acknowledges risks from policy changes in the pharmaceutical industry that could impact demand for its products[120]. - The company faces intensified competition in the domestic pharmaceutical equipment market, particularly from established foreign manufacturers[120]. - The company is committed to optimizing its management system and establishing a scientific compensation management system to attract and retain talent[122]. - The company is focused on ensuring project progress and quality to mitigate risks associated with fundraising project implementation[123]. - The company has committed to enhancing compliance awareness regarding the use of raised funds following recent warnings issued to certain executives[185]. Corporate Governance - The company has a governance structure that includes a board of 9 members, with 3 independent directors, complying with legal and regulatory requirements[130]. - The company held multiple shareholder meetings in 2024, with participation rates ranging from 32.83% to 35.23%[135]. - The company completed a board election on July 23, 2024, resulting in the appointment of several new directors and executives[139]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.49 million[146]. - The decision-making process for remuneration involves the shareholders' meeting for directors and supervisors, while the board decides for senior management[145]. - The independent directors include 樊德珠, 许小明, and 郑高利, each receiving CNY 72,000[146]. - The company has maintained a stable management team with no significant changes in shareholding among directors and executives during the reporting period[137]. - The company emphasizes close communication with the original management teams of the acquired subsidiaries to ensure stability and synergy in operations[124]. Research and Development - The company has established a comprehensive service capability across the entire pharmaceutical value chain, including information consulting, pharmaceutical research, equipment support, and clinical trials[62]. - The company aims to enhance its service capabilities and expand its market share by integrating upstream and downstream resources and improving equipment quality[41]. - The company is committed to building a digital capability matrix covering drug discovery, process development, and quality control to support the pharmaceutical 4.0 era[113]. - The company will strengthen its R&D capabilities by collaborating with universities to meet or exceed new GMP standards and enhance product intelligence[114]. - The company has developed a fully automated buffer liquid dispensing system, enhancing product efficiency and market competitiveness[85]. - The company has completed the development of a continuous production equipment for solid oral dosage forms, integrating filtration, washing, and drying processes into one machine, enhancing product efficiency and market competitiveness[84]. - The company is focusing on the optimization of high-efficiency stirring and extrusion screw structures for large-scale hot melt extrusion production lines, aiming for intelligent control technology[84]. - The company's R&D investment amounted to ¥80,755,686.14 in 2024, representing 5.84% of operating revenue, a decrease from 8.00% in 2023[87]. Market Position and Strategy - The company operates in the pharmaceutical equipment industry, which is characterized by strong demand and minimal seasonality[28]. - The company is a leader in the manufacturing of intelligent factory equipment for oral solid dosage forms, providing comprehensive solutions to pharmaceutical enterprises[28]. - The company has established a solid customer base, serving over 50 countries and regions, including well-known pharmaceutical and healthcare enterprises[28]. - The company aims to become a leading supplier of intelligent factory solutions in the pharmaceutical equipment market by 2025, focusing on solid preparation and health industry strategies[112]. - The company plans to enhance its product offerings in biopharmaceuticals, including improvements in medical water purification systems and related equipment[112]. - The company will increase investment in new product development and capacity expansion, targeting high-end manufacturing and automation[113]. - The company is focused on developing new products and technologies to meet the demands of both domestic and international high-end clients[63]. Internal Control and Audit - The internal control system has been updated and improved, effectively preventing operational risks and enhancing management oversight[165]. - No significant internal control deficiencies were reported during the period, with zero major defects identified in both financial and non-financial reporting[170]. - The internal control audit report confirmed that the company maintained effective financial reporting controls as of December 31, 2024[170]. - The company has appointed Zhonghui Certified Public Accountants as the internal control auditing firm, with a fee of 200,000 RMB[182]. Investment and Financing - The company raised a total of CNY 27,000.00 million through a non-public offering, with a net amount of CNY 26,186.23 million after deducting fees[102]. - As of December 31, 2024, the company had used CNY 16,297.69 million of the raised funds, with a remaining balance of CNY 10,799.32 million[103]. - The company has ongoing construction projects, including the "High-end Intelligent Medical Equipment Production Base" and "Pharmaceutical Liquid Preparation System Production Center" funded by self-raised capital and non-public offering funds[98]. - The total amount of guarantees approved during the reporting period is 35,000 million[199]. - The actual amount of guarantees that occurred during the reporting period is 6,960 million[199]. - The total amount of guarantees at the end of the reporting period is 9,985 million[199]. - The company has provided guarantees for loans to its controlling subsidiaries, with financial risks being within controllable limits[200]. Employee and Talent Management - The total number of employees at the end of the reporting period is 1,640, with 660 in the parent company and 980 in major subsidiaries[157]. - The company maintains a performance-based salary policy, linking compensation to individual and team performance[158]. - The company plans to enhance training programs in 2025, focusing on employee development and aligning with its core values[159]. - The company has a total of 48 employees with a postgraduate degree, highlighting its investment in skilled talent[157]. Environmental and Social Responsibility - The company has not faced any major environmental penalties during the reporting period and complies with relevant environmental laws[172]. - The company has not yet initiated any poverty alleviation or rural revitalization efforts during the reporting period[175]. - The company actively respects and protects the rights of stakeholders, promoting a balanced development approach[132].

国投证券股份有限公司 关于浙江迦南科技股份有限公司 2025 年度使用闲置自有资 金和闲置募集资金进行现金管理的核查意见 国投证券股份有限公司（以下简称"国投证券"、"保荐机构"）作为浙江迦 南科技股份有限公司（以下简称"公司"、"迦南科技"）2020 年度向特定对象发 行股票的保荐机构，根据《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和 规范性文件的规定，对迦南科技及其控股子公司拟使用闲置募集资金和闲置自有 资金进行现金管理的事项进行了审慎核查，核查的具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意浙江迦南科技股份有限公司向特定对 象发行股票注册的批复》（证监许可[2021]1175 号），同意公司向特定对象发行股 票的注册申请。公司向 12 名特定对象发行人民币普通股（A 股）股票 35,573,122 股，发行价格 7.59 元/股，募集资金总额为人民币 269,999,995.98 元，扣除各项 发行费用人民币 8,137, ...

浙江迦南科技股份有限公司 2024 年度独立董事述职报告 （樊德珠） 各位股东及股东代表： 本人作为浙江迦南科技股份有限公司（以下简称"公司"）的独立董事，2024 年度，严格按照《公司法》、《上市公司治理准则》、《上市公司独立董事管理 办法》和《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等有关法律法规以及《公司章程》、《公司独立董事工作制度》的规定 和要求，勤勉尽职、恪尽职守，积极出席股东大会、董事会和董事会各专门委员 会会议，认真审议各项议案，从专业角度为公司的经营决策和规范运作提出独立 意见与合理化建议，努力维护公司的整体利益和股东尤其是中小股东的合法权益。 现将 2024 年度履行独立董事职责情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人樊德珠，1966 年出生，研究生学历，高级律师，中国国籍，无境外永 久居留权。曾任杭州民生财团、浙江中大控股集团有限公司总裁办经理、浙江钱 江律师事务所合伙人、律师；现任浙江锦丰律师事务所主任，浙江省律协常务理 事、浙江省律协执业权益保障委员会副主任、浙江省律协女律师工作委员会主任、 杭州市第十 ...

浙江迦南科技股份有限公司 2024 年度独立董事述职报告 （郑高利） 各位股东及股东代表： 本人作为浙江迦南科技股份有限公司（以下简称"公司"）的独立董事，2024 年度，严格按照《公司法》、《上市公司治理准则》、《上市公司独立董事管理 办法》和《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等有关法律法规以及《公司章程》、《公司独立董事工作制度》的规定 和要求，勤勉尽职、恪尽职守，积极出席股东大会、董事会和董事会各专门委员 会会议，认真审议各项议案，从专业角度为公司的经营决策和规范运作提出独立 意见与合理化建议，努力维护公司的整体利益和股东尤其是中小股东的合法权益。 现将 2024 年度履行独立董事职责情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人郑高利，1963 年出生，博士研究生，研究员，中国国籍，无境外永久 居留权。曾任浙江省医学科学院药物研究所副所长、所长、浙江省医学科学院安 评中心主任等；现任公司独立董事。 （二）独立性说明 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务， ...

浙江迦南科技股份有限公司 董事会关于独立董事独立性情况的专项意见 浙江迦南科技股份有限公司董事会 2025 年 4 月 17 日 1 浙江迦南科技股份有限公司（以下简称"公司"）董事会根据《上市公司独 立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等要求，并结合独立董事出具的《独立董事独立性自查情况 表》，就公司在任独立董事的独立性情况进行评估并出具如下专项意见： 经核查，公司独立董事均能够胜任独立董事的职责要求，其未在公司担任除 独立董事以外的任何职务，也未在公司主要股东公司担任任何职务，与公司以及 主要股东之间不存在妨碍我们进行独立客观判断的关系，不存在影响独立董事独 立性的情况，符合《上市公司独立董事管理办法》、《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规、规范性文件 及《公司章程》中关于独立董事的任职资格及独立性的相关要求。 ...

各位股东及股东代表： 本人作为浙江迦南科技股份有限公司（以下简称"公司"）的独立董事，2024 年度，严格按照《公司法》、《上市公司治理准则》、《上市公司独立董事管理 办法》和《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等有关法律法规以及《公司章程》、《公司独立董事工作制度》的规定 和要求，勤勉尽职、恪尽职守，积极出席股东大会、董事会和董事会各专门委员 会会议，认真审议各项议案，从专业角度为公司的经营决策和规范运作提出独立 意见与合理化建议，努力维护公司的整体利益和股东尤其是中小股东的合法权益。 现将 2024 年度履行独立董事职责情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人许小明，1972 年出生，本科学历，注册会计师，资产评估师，税务师， 中国国籍，无境外永久居留权。曾任宁波菲尔德皮革制品有限公司主办会计、慈 溪铭正会计师事务所审计经理等；现任慈溪弘正会计师事务所有限公司副主任会 计师，公司独立董事。 （二）独立性说明 浙江迦南科技股份有限公司 2024 年度独立董事述职报告 （许小明） 2024 年度，公司召开董事会 9 次，股 ...

迦南科技（300412）公告，2024年营业收入13.83亿元，同比增长32.09%。归属于上市公司股东的净利 润3626.7万元，同比增长254.77%。基本每股收益0.07元/股，同比增长240.00%。公司拟以4.98亿为基 数，向全体股东每10股派发现金红利0.6元(含税)，送红股0股(含税)，以资本公积金向全体股东每10股 转增0股。 ...

Financial Performance - The total operating revenue for 2024 reached CNY 1,383,110,540.27, representing a 32.09% increase compared to the previous year[3] - The total profit amounted to CNY 35,544,842.89, showing a significant increase of 244.33% year-on-year[3] - The net profit attributable to shareholders was CNY 36,172,553.71, reflecting a 254.36% increase from the previous year[3] - The net profit after deducting non-recurring gains and losses was CNY 23,181,339.94, which is a 161.54% increase compared to the same period last year[3] - The basic earnings per share improved to CNY 0.07, up 240.00% from a loss of CNY 0.05 in the previous year[3] - The weighted average return on net assets increased to 3.50%, a rise of 5.78 percentage points from -2.28%[3] Assets and Equity - Total assets at the end of the reporting period were CNY 2,481,748,996.64, down 4.47% from the beginning of the period[4] - Shareholders' equity attributable to the company increased to CNY 1,051,852,738.18, up 3.56% from the beginning of the period[4] Business Strategy - The company focused on enhancing its technical marketing capabilities and project management, leading to increased business delivery volume and revenue growth[4] - The company confirmed that there are no significant discrepancies between the reported performance and previous forecasts[5]

300412 证券代码：300412 证券简称：迦南科技 公告编号：2025-006 浙江迦南科技股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江迦南科技股份有限公司控股孙公司凯贤制药设备（南京）有限公司（以 下简称"南京凯贤"）于近日收到江苏省科学技术厅、江苏省财政厅、国家税务 总 局 江苏省 税务局联合颁发的《高新技术企业证书》，证书编号为 GR202432010288，发证日期为 2024 年 12 月 16 日，有效期三年。 根据国家对高新技术企业的相关税收优惠政策，南京凯贤自获得高新技术企 业资格起连续三年可享受高新技术企业所得税优惠政策，即按 15%的税率缴纳企 业所得税。 特此公告。 浙江迦南科技股份有限公司董事会 1 关于控股孙公司获得高新技术企业证书的公告 2025 年 2 月 18 日 ...